—结直肠癌早筛龙头，更多大单品即将兑现：精密科学

Investment Rating - The industry investment rating is optimistic (maintained) [1] Core Insights - Precision Science is a leader in colorectal cancer early screening and is transitioning to a tumor screening platform. The company has developed the first commercially available mt-sDNA colorectal cancer screening product, Cologuard, in the U.S. The revenue primarily comes from screening business (centered around Cologuard) and precision tumor detection (centered around the Oncotype Dx series), achieving $2.05 billion in revenue for Q1-3 2025, a 16% year-on-year increase. Although the company has not yet achieved net profit, free cash flow (FCF) is consistently positive, with an adjusted EBITDA margin of 14% expected to exceed 20% by 2027, indicating potential for accelerated profit realization [2][4]. Summary by Sections Company Overview - Precision Science focuses on developing colorectal cancer early screening products, with Cologuard being the flagship product approved by the FDA in 2014. The company also expanded into precision tumor detection through the acquisition of Genomic Health in 2019. As of 2024, the revenue breakdown is 76% from screening and 24% from precision tumor detection [8][61]. Industry Situation - The colorectal cancer early screening industry is crucial for early detection, significantly reducing cancer risk. The U.S. Preventive Services Task Force (USPSTF) recommends regular screening for individuals aged 45-75, targeting over 100 million people. The screening rate for those aged 50 and above is expected to exceed 70%, while approximately 50 million individuals aged 45-85 have not undergone screening, indicating a substantial market opportunity [3][33][43]. Cologuard's Market Position - Cologuard has gained rapid adoption since its FDA approval, benefiting from insurance coverage and guideline recommendations. The product has undergone upgrades, with the latest version, Cologuard Plus, showing improved performance and a 16% price increase. The company invests over $100 million annually in advertising and has a sales team of over 1,400, enhancing connections with healthcare providers and patients [3][57][80]. Future Growth Potential - Precision Science's pipeline includes MRD and multi-cancer early screening products expected to launch in 2025, which are anticipated to contribute to long-term growth despite limited short-term revenue impact. The blood test product is expected to be approved by the FDA in 2026, further solidifying the company's leadership in colorectal cancer early screening [2][4][93]. Oncotype Dx Series - The Oncotype Dx series, which assesses cancer recurrence risk, has a 90% penetration rate in the U.S. and is expected to grow internationally. The series includes tests for breast and colon cancer, with significant revenue contributions from the breast recurrence score test [95][97].